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LBPI: A WEB INTERFACE FOR THE IDENTIFICATION OF ALLOSTERIC
LIGAND BINDING SITES

Nabina Paudyal (MS)
Supervisory Professor: Alemayehu Gorfe, PhD

The development of efficient tools for allosteric ligand binding site identification in
potential drug targets is an important step for computational drug design. Ligand binding
specificity analysis (LIBSA) is one of the protocols that utilizes filtering algorithms to assess
the propensity of a site on a target structure or structures to bind a ligand. However, LIBSA
requires expert skills to be properly executed. Thus, a Web interface, LBPI (Ligand Binding
Pocket Identification) has been developed using Django, a Python based web framework. A
Python Wrapper has also been developed to streamline pre-existing algorithms of LIBSA. The
Wrapper helps in the preparation of files, execution of individual programs and generation of
appropriate results. LBPI provides an ideal platform for making complex binding site
identification protocols readily available for non-expert users to submit jobs and monitor the
results. The goal of LBPI is to integrate available algorithms in a systematic way and make it
easily available for both experts and non-experts.

v

TABLE OF CONTENTS

APPROVAL PAGE ................................................................................................................... i
ACKNOWLEDGEMENTS ..................................................................................................... iii
LIST OF TABLES ................................................................................................................. viii
LIST OF FIGURES ................................................................................................................. ix
CHAPTER 1
INTRODUCTION TO STRUCTURE-BASED DRUG
DISCOVERY .......................................................................................................................1
1.1
Computational ligand design ...................................................................................1
1.2
Structure based computer-aided drug design ...........................................................3
1.3
Molecular docking and scoring function .................................................................5
1.4
Targeting of an active site versus allosteric site ......................................................7
1.5
Approaches for allosteric ligand binding site identification ....................................7
CHAPTER 2

LIGAND BINDING SPECIFICITY ANALYSIS .........................................9

CHAPTER 3
LBPI: A WEB INTERFACE .......................................................................14
3.1
Overview ................................................................................................................14
3.2
Python programming and its modules used as a Wrapper .....................................15
3.3
Django and its work structure used for web design ...............................................15
CHAPTER 4
IMPLEMENTATION OF LBPI ..................................................................18
4.1
Overview ................................................................................................................18
4.2
Implementation of blind docking and filters (option 1): ........................................20
4.2.1 Processing coordinate files ..............................................................................20
4.2.2 Docking of the probe on the entire surface of the target protein .....................22
4.2.3 LIBSA filters ....................................................................................................26
4.2.4 Ensemble-based SNR.......................................................................................29
4.3
Implementation of filters (option 2) .......................................................................30
4.3.1 File preparation ................................................................................................30
4.3.2 LIBSA filters ....................................................................................................31
4.4
Summary ................................................................................................................31
CHAPTER 5
APPLICATIONS .........................................................................................33
5.1
Re-docking with LBPI ...........................................................................................33
5.2
Cross-docking with LBPI ......................................................................................36
5.3
Identification of binding sites of test ligands with LBPI .......................................43
5.4
Identification of the binding preferences of estrogens with LBPI .........................46
5.5
Identification of allosteric ligand binding site for sorafenib on p38
through LBPI .........................................................................................................51
CHAPTER 6

CONCLUSIONS AND FUTURE DIRECTIONS.......................................53
vi

REFERENCES ........................................................................................................................56
VITA ........................................................................................................................................66

vii

LIST OF TABLES

Table 1. Summary of re-docking results with LBPI ................................................................36
Table 2. Relative binding affinity for estrogen compounds from literature and
summary of results obtained from LBPI. ...............................................................48

viii

LIST OF FIGURES

Figure 1.1 Timeline for drug discovery .................................................................................... 1
Figure 1.2. Workflow of SB-CADD ......................................................................................... 3
Figure 2.1. Schematic outline of the LIBSA workflow, with the filters for the quantification
of binding site preference.......................................................................................................... 9
Figure 2.2. Blind docking of a ligand 0QV ((4-hydroxypiperidin-1-yl)(1H-indol-3-yl)
methanethione) on the entire surface of GDP-bound K-Ras structure from PDB id 4EPW.
Dense black dots represent poses of the probe ligand that might represent a probable binding
site. The sparsely occupied region represented by fewer black dots might represent docking
noise. ....................................................................................................................................... 10
Figure 3.1. The workflow of the Django framework. ............................................................. 16
Figure 4.1. Front-page of LBPI with two options of use highlighted in box 1. Manual is made
available in the page through the link highlighted in box 2. ................................................... 18
Figure 4.2. A schematic outline of the workflow of LBPI. .................................................... 19
Figure 4.3. Choices for submitting coordinate files that are for both the target receptor and
the probe ligand as in the red boxes 1 and 3. Red box 2 represents a list of PDB chain
identifiers and co-crystals that exist in the target structure returned to the user for selection.
For docking, the blue box highlights example files provided for demonstration purposes. ... 20
Figure 4.4. Python snippet from Django Views representing a function which accepts and
returns user requests for submitting files via the Web interface. ............................................ 21
Figure 4.5. A Python snippet from the “Wrapper” for extracting chain identifiers and residue
names to facilitate returning of a list of chain identifiers and co-crystals to the user............. 22
Figure 4.6. Parameters required for blind docking shown in the red box. Blue box highlights
downloadable ligand coordinate files generated by LBPI. ..................................................... 23
Figure 4.7. Python snippet from Django Views showing the method used to accept input
parameters. .............................................................................................................................. 24
ix

Figure 4.8. Python snippet from the “Wrapper” representing system arguments for passing
parameter values retrieved from the framework shown in Figure 4.7. ................................... 24
Figure 4.9. Python snippet from the “Wrapper” showing the passing of parameter values
through system arguments to invoke Python scripts present in MGL Tools of AutoDock for
preparing parameter files needed for docking. ....................................................................... 24
Figure 4.10. Grid box mapping the surface of the protein with its center overlapping the
center of the protein. ............................................................................................................... 25
Figure 4.11. LBPI facilitates selection of LIBSA filters with parameters for corresponding
selected filters as shown in red boxes. Blue box 1 represents processed log files available for
download, which can be viewed with any graphical interface. Histograms provided in blue
box 1 represent affinity and contact spectra obtained from docking without utilizing filters.
Histograms in blue box 2 represent affinity and contact spectra after applying LIBSA filters.
SNR values are provided along with the residues representing the region of interest. .......... 27
Figure 4.12. Python snippet of scripts written for preparing NumPy array used by Matplotlib
as pl for preparing histogram. ................................................................................................. 28
Figure 4.13. Python snippet from Django framework for selecting filters. ............................ 29
Figure 4.14. Uploading multiple conformations to calculate SNR by averaging over an
ensemble. ................................................................................................................................ 30
Figure 4.15. Options for submitting files of the receptor and log files from docking is
highlighted in the red box with example files highlighted in the blue box............................. 31
Figure 5.1. Chemical structures of ligand 0QV, SB2, and EST from PDB 4EPW, 1QKT and
1A9U respectively. ................................................................................................................. 34
Figure 5.2. (A-C) Contact histograms after applying affinity and highpass filter to remove
docking noise (left). The target structure shown in grey surface with the co-crystallized
ligand is represented in red and the docked poses in black dots; SNR for the region of interest
is shown in the right panel and is highlighted in green on the protein surface, which coincides
with the co-crystal site. ........................................................................................................... 35
Figure 5.3. Contact histogram after affinity and high pass filtering of docking results for NIL
(3GP0) to protein kinase P38 (1A9U). ................................................................................... 37
x

Figure 5.4. Chemical structures of ligands 0QR, 0QW, OQX and BZI from PDB 4EPX,
4EPT, 4EPV and 4DSU respectively ...................................................................................... 38
Figure 5.5. Docked poses obtained from AutoDock for 0QR (blue), 0QW (yellow), 0QX
(red) and BZI (green). Regions 1 and 2 are represented by pink and cyan color respectively
and indicate the binding regions of interest for calculating SNR for each ligand. ................. 39
Figure 5.6. Panels A, B, C, and D represent contact histograms for 0QR, 0QW, 0QX and BZI
after docking on K-Ras (4EPW) and applying both affinity and high pass filters. SNR
computed for region 1 is represented in pink and SNR computed for region 2 is represented
in cyan. .................................................................................................................................... 40
Figure 5.7. Contact histograms for 0QR and 0QW obtained from docking these ligands to the
parent protein X-Ray structure. SNR for region 1 and region 2 is represented as pink and blue
respectively. ............................................................................................................................ 41
Figure 5.8. Contact histograms after blind docking of 0QR on five K-Ras conformers (A to
E) and a single averaged contact histogram (F). ..................................................................... 42
Figure 5.9. Contact histograms after blind docking of 0QW on five K-Ras conformers (A to
E) and a single averaged contact histogram (F). ..................................................................... 43
Figure 5.10. Contact histograms for three test ligands promazine (A), E22 (B) and V2 (C)
docked on X-Ray structure 4EPW of K-Ras. ......................................................................... 44
Figure 5.11. Contact histograms after blind docking of E22 on five K-Ras conformers (A to
E) and a single averaged contact histogram (F). ..................................................................... 45
Figure 5.12. Contact histograms after blind docking of V2 on five K-Ras conformers (A to E)
and a single averaged contact histogram (F)........................................................................... 46
Figure 5.13. Chemical structure of estrogen compounds ....................................................... 49
Figure 5.14. Contact histograms obtained after applying affinity and high-pass filters to
remove docking noise for estrogen compounds to estrogen receptor (1QKT). ...................... 50
Figure 5.15. Contact histogram after affinity and high pass filtering of docking results for
sorafenib to its protein kinase P38 (3HEG) shown in left panel, structure of P38 with docked
poses in yellow, three identified region from LBPI, co-crystal (sorafenib) in red, and
xi

chemical structure of sorafenib in right panel. ........................................................................ 52

xii

CHAPTER 1
INTRODUCTION TO STRUCTURE-BASED DRUG DISCOVERY

The process of structure-based drug discovery, as outlined in Figure 1.1 starts with basic
research towards investigating the effect of potential drug candidates on an identified
druggable target. First, basic research is performed to identify appropriate disease-causing
targets or druggable targets such as proteins. Compounds are then screened to identify potential
hits and eventually identify a drug lead, which is further subjected to pre-clinical and clinical
trials, and finally filing for approval by the Food and Drug Administration. The new drug
introduced to the market is administered to patients ensuring its safety, potency, and
bioavailability .

Figure 1.1 Timeline for drug discovery
1.1

Computational ligand design
Experimental screening approaches can be used to identify compounds for druggable

targets but they can often be expensive and time-consuming (2). In addition, the number of
druggable targets has increased enormously over the past 50 years (3). In this period,
computational biology has made tremendous advances in facilitating drug discovery by
1

expediting the process and reducing cost. Various in silico applications have been introduced
that are collectively referred to as computer aided drug design method (CADD) (4). FDA
approved drugs required billions of dollars using traditional research and methodologies, and
thus discovery of new drugs has been declining since 1950 (5), which can be partly reversed
through the use of CADD. The introduction of CADD also provided opportunities for
developing novel techniques to enhance better understanding of drug mechanisms and improve
efficiency (6).
There are two major techniques used in CADD: a) ligand-based computer aided drug
design (LB-CADD) and b) structure-based computer aided drug design (SB-CADD) (7). LBCADD is a statistical approach that relies on structure-activity relationship information
between existing ligands and their targets. This technique can also be used as an indirect drug
design method that does not directly use knowledge of the target of interest and thus becomes
more challenging if there is no known ligand for the target of interest. In this case, SB-CADD
is typically a better approach (8). SB-CADD requires the 3D structure of the target for the
identification of new chemical compounds. In 1973, Beddell and Goodford reported the first
structure-based drug design method for designing compounds that emulate the function of 2-3
diphosphoglycerate in human hemoglobin (9-11). Compounds that can modulate the function
of the target by binding with high affinity and selectivity have a higher chance of becoming
hits (7, 12, 13). A key aspect of SB-CADD is the development of efficient strategies for
identifying potential hits through high throughput virtual screening (HTVS) involving
molecular docking and calculation of scoring functions. SB-CADD also allow us for a detailed
2

understanding of the interaction in ligand-target complexes, and for addressing conformational
changes of both compound and target (14, 15). The identified hits are further subjected to
experimental procedures like biochemical or biophysical assays and undergo optimization
before they become drug leads (Figure 1.2).

Figure 1.2. Workflow of SB-CADD
1.2

Structure based computer-aided drug design
Application of SB-CADD (or any other similar technique) requires a 3D structure of

the target macromolecule, which can be obtained from X-ray crystallography or NMR
spectroscopy (16, 17). X-ray crystallography offers detailed yet static information about the
target structure while NMR provides an ensemble of structures for relatively small proteins
(17). The structures of macromolecules obtained from these and other methods are deposited
in the protein data bank (PDB) (18). PDB, the most commonly used database for protein
3

structure, was established in 1971 at the Brookhaven National Laboratory and the data
deposited were maintained in Brookhaven, Tokyo, and Cambridge. At present PDB is managed
by members of the Research Collaboration for Structural Bioinformatics (RCSB) consortium
based at Rutgers and UC San Diego (16, 18). The first reported 3D protein structure was Xray structure of sperm whale myoglobin published in 1958, and deposited to the PDB as PDBid 1MBN in 1973 by Kendrew and Watson (11, 16, 19, 20). Statistics of yearly growth of total
structure show an exponential growth with more than 125,000 biological macromolecules
currently available in the PDB. These structures are solved by X-Ray crystallography or NMR.
Comparative or homology modeling may also help in providing information about large
macromolecules whose structure remains unidentified by experimental methods (21). While
some experimental methods might be able to account for receptor flexibility, it is expensive to
generate multiple structures for each macromolecule. Molecular dynamics simulations can be
used to generate large conformations of target structures to account for its dynamic nature (22).
Representative structures of these large number of conformations from MD can be generated
through various methods, such as RMSD clustering and principal component analysis (23, 24).
Availability of ligand libraries is another important component of SB-CADD. Several
repositories of chemical compounds are available. Some of the compounds in these libraries
possess drug-like properties satisfying Lipinski’s Rule of 5: a drug-like compound should
possess less than five hydrogen bond donors, less than ten hydrogen bond acceptors, should
have a molecular weight of 500 Daltons or less and a logP (calculated log of octanol-water
partition coefficient) less than 5 (25, 26). Examples of chemical databases include PubChem,
4

a database of 25 million unique compounds with annotations about their biological activities
(27). Others include ZINC (28) and ChemDB (29), containing about 21 million and 5 million
compounds respectively, with Vendor’s catalog (12, 28, 29).

1.3

Molecular docking and scoring function
Molecular docking is widely used in structure-based drug design for the identification

of compounds that interact with the target of interest by characterizing its binding mode and
calculating its binding energy. The earliest reported molecular docking was in 1982, on two
systems: interaction of heme with myoglobin, and binding of thyroid hormone analogs to
prealbumin. At that time, both the macromolecule and the ligand were treated as a rigid body
during docking (11, 30, 31). Molecular docking can be used for a) site-directed docking, which
refers to docking of molecules at a specific site of the target for virtual screening of chemical
compounds to identify potential hits or b) blind docking, which refers to docking of probe
molecules or ligands on the entire surface of the target to identify an appropriate binding site.
The most common molecular docking programs currently used are AutoDock (32, 33), GOLD
(34), FlexX (35), DOCK (36). Binding energy typically obtained from molecular docking is
calculated using a physics-based scoring function (33).
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Where ΔGbinding refers to the binding energy or the scoring function that depends on a
12-6 Lennard-Jones potential (vdW) for non-polar interactions, a modified 12-10 LennardJones potential for hydrogen bonding interactions (hbond), a couloumb term for electrostatic
interactions (elec), as well as torsional (tor) and solvation energy (sol). The ΔW coefficient for
each interaction term is calculated by linear regression analysis of known protein-ligand
complexes. Aij and Bij represent constants for the Lennard-Jones potential, which depend on
the strength of van der Waals interaction between two atoms i and j with equilibrium distance
rij (37). Whereas Cij and Dij represent constants for a modified Lennard-Jones potential with
their value depending on the interaction between atoms i and j through H-bonding (33). E(t)
represents directionality based on hydrogen bonding angle. The charges on atoms i and j are
represented by qi and qj with Ɛ being the dielectric constant of the medium. The number of
torsions of the ligand is represented by Ntor and depends on the number of its sp3-hybridized
bonds. Finally, the solvation term is atom specific and is represented as Si for an atom i with
fragmental volume Vi. The constant term σ in the calculation of solvation energy is a Gaussian
distance of value is 3.5 Å (33).
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1.4

Targeting of an active site versus allosteric site
Referring back to the workflow of SB-CADD shown in Figure 1.2, before the

identification of potential hits it is very important to identify a feasible binding site on an
appropriate druggable target, without which identification of a drug lead is very challenging
(38, 39). Druggable targets, which are typically proteins, bind to other macromolecules like
proteins or small molecules to execute their functions (17). Molecules binding to the active site
can have high specificity and usually bind with high affinity (17). However, many drugs
designed to target the active site and inhibit function might produce toxic effects by binding to
other proteins with a structurally similar active site (40). An alternative approach is to alter
the function of the target protein via allosteric modulation (40, 41). Allosteric sites are distinct
binding sites from the active site and can be feasible sites for developing novel drugs. When
an allosteric ligand binds to the allosteric site it could modify the active site and thereby alter
the function (42, 43). The mechanism for allosteric binding is well elucidated with the analysis
of the available 3D structures of proteins (44). Drugs targeting allosteric sites are generally
less toxic and have greater selectivity, and hence allosteric binding site identification is an
important endeavor in current SB-CADD. (41).

1.5

Approaches for allosteric ligand binding site identification
FTMAP (45), MDpocket (46), Sitemap (47), pMD (48), and LIBSA (49) are some of

the approaches commonly used for allosteric ligand binding site identification. FTMAP is
based on a fast Fourier transform (FFT) correlation approach for sampling consensus site on
7

the entire surface of the protein using small organic probe molecules. The speed with which it
solves detailed energy expressions used for scoring protein-probe interactions makes this
approach unique (45). MDpocket is a geometry based cavity detection approach based on the
f-pocket algorithm. It helps in the identification and characterization of binding cavities that
might be transiently present in MD trajectories or ensembles of protein conformations (46).
On the other hand, Sitemap helps in the prediction and classification of target druggability
based on ligand binding efficiency. In this method, site points are located on the protein’s
surface, followed by the preparation of contours representing the nature of the site and hence
prediction and classification of sites (47). pMD-membrane (48) and LIBSA (49) techniques
developed previously in our lab utilize MD ensembles for identifying allosteric binding
pockets. In pMD-membrane, MD is performed in the presence of small molecular probes to
assess the propensity of a site on a soluble or membrane bound protein to bind a ligand. In this
method, probe occupancy is used for evaluating druggability of a binding site, and modified
force field parameters are introduced between selected probe and membrane atoms to mitigate
potential effects of the probe molecules on the membrane (48). LIBSA utilizes three steps to
identify binding sites: a) blind docking of the ligand onto a target receptor, b) application of
filters on docked poses, and c) use of signal to noise ratio for quantification of binding site
preferences (49).
Since LIBSA is the primary tool used for allosteric ligand bind site identification in
this project, the next chapter provides a detailed description of this technique.
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CHAPTER 2
LIGAND BINDING SPECIFICITY ANALYSIS

Ligand binding specificity analysis (LIBSA) (49) is a novel approach for addressing
the challenge of ranking blind docked results designed to identify preferred binding site(s).
The general workflow of LIBSA starts with the processing of coordinate files of a target
receptor (a single or multiple conformations) and a probe ligand followed by blind docking
using AutoDock or any other docking algorithm (the original paper utilizes AutoDock for blind
docking). Filtering algorithms were introduced (affinity filter and high pass filter) to remove
docking noise and to prioritize poses, followed by quantification of binding site preferences.
The flowchart in Figure 2.1 provides a schematic outline of LIBSA.

Figure 2.1. Schematic outline of the LIBSA workflow, with the filters for the quantification of
binding site preference.
Blind docking, which is the key component of LIBSA, refers to the identification of
probable binding sites by docking probe molecules on the entire surface of the target.
AutoDock, the most cited docking program in the literature, was first used for blind docking
by Csaba Hetényi and David van der Spoel (50, 51). The basic procedure for blind docking
9

using AutoDock involves processing structure files for the probe ligand and the target molecule
by adding Gasteiger charges and hydrogen atoms, and removing water molecules, ions and
metals (if any). A grid, which is important for defining the search space, is built on a threedimensional box covering the entire protein with the center of the box overlapping with the
center of the protein. This is done by means of AutoGrid. Lamarckian Genetic Algorithm
(LGA), a common and efficient search method in AutoDock, determines the termination
criteria based on the number of energy evaluations or the number of generations, whichever
comes first (32, 33). Ultimately, conformations for the best binding mode of the ligand are
obtained and their corresponding binding free energy is returned to the user as a log file.

Figure 2.2. Blind docking of a ligand 0QV ((4-hydroxypiperidin-1-yl)(1H-indol-3-yl)
methanethione) on the entire surface of GDP-bound K-Ras structure from PDB id 4EPW.
Dense black dots represent poses of the probe ligand that might represent a probable binding
site. The sparsely occupied region represented by fewer black dots might represent docking
noise.

10

Two filters, namely affinity filter and high pass filter, were developed in order to
facilitate analysis of blind docking results. The filters use the log file (dlg format) from the
docking program to remove docking noise. Filtering signal from noise is the most novel aspect
of LIBSA (49). Each filter works in a different way but serves the same purpose: remove
docking noise. Affinity filter reduces docking noise by utilizing docking free energy values.
Since energy values calculated through docking programs typically entail an error of 2kcal/mol
(32, 52), accounting for binding preference based on the energy alone is not effective. Affinity
filter addresses this challenge by considering the frequency of occurrence of docking scores.
Firstly, an affinity histogram is prepared based on the distribution of binding scores, and a
cutoff value is introduced to focus on the most prominent peaks. Peaks with frequency of
occurrence more than or equal to cutoff value are identified as explicit peaks. Then for further
analysis, peaks within a certain sampling window of the explicit peaks are included as auxiliary
peaks. The docked conformations corresponding to the explicit and auxiliary peaks represent
filtered poses based on affinity filtering. The second filter is a high-pass filter that utilizes the
concept of digital signal processing for removing noise. It is based on the frequency of contact
between heavy atoms of the probe molecule and heavy atoms of residues of the protein that lie
within a certain distance. This histogram is presented as input for the filter. A cutoff for peak
value is once again used to focus on the residue that interact most frequently with the ligand.
The flowchart for utilization of LIBSA filters is shown in the right panel of Figure 2.1. The
two filters can be used independently or together for reducing docking noise.
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Calculating the signal-to-noise (SNR) ratio is the final step of LIBSA. SNR helps to
quantify binding site preference. With the calculation of SNR, a best binding site out of
probable multiple binding sites can be identified, or ligands can be ranked for their preference
to bind a site based on their SNR values. A contact histogram is required for computing SNR,
and is prepared by considering the frequency of contacts between heavy atoms of the probe
molecule and heavy atoms of residues of the protein that lie within a certain cutoff distance.
With the application of LIBSA filters, filtered poses are utilized for preparing contact
histogram from which the identified region of interest is considered as signal and other regions
are considered as noise. SNR is calculated as,

 N noise  ui 
SNR  log10  signal

 N
 u j 
where ui is the height of the peak of residue i in the region of interest (considered as
signal), Nsignal is the total number of residues that lie within the same patch, uj represents the
height of the peak of residue j that is outside the signal region and Nnoise represents the total
number of residues that lie outside the signal patch.
Ensembles-based SNR involves calculation of SNR over multiple representative
conformations of a target of interest. Identification of a preferred binding site of an ensemble
by utilizing LIBSA involves independent docking on each target conformation, followed by
application of filters to each independent molecular dockings and averaging of the results to
produce a single contact spectrum. The averaged spectrum is then utilized for calculating SNR
as described above.
12

LIBSA was applied to several sets of known protein-ligand complexes for validation.
Few sets of probe-ligands were used on Ras protein conformations obtained from the PDB or
MD simulation for re-identification of binding sites to test the robustness of LIBSA. In
addition, andrographolide derivatives were used as ligands with K-Ras ensemble for
quantification of preferred binding sites, and the ligands were ranked based on their binding
preference of those ligands to a site. Hence, LIBSA can be applied in any challenging drug
target for the identification of binding site or can be applied with diverse ligands for ranking
them based on their preference to bind to a site.
However, application of LIBSA, which entails processing of files, performing blind
docking, applying filters to reduce docking noise, and quantifying binding site preferences by
calculating SNR, requires expert skills to be properly executed. The minimum skills required
for the execution of LIBSA include, processing of structure files in appropriate file formats,
setting grid and docking parameters, executing LIBSA algorithms written in C++
programming language, preparing histograms and providing values to the algorithms for
calculation of SNR. Thus, LIBSA is not easily accessible to non-experts. Hence, to reduce the
significant learning curve and make accessible to both experts and non-experts, we
hypothesized that, a web interface for streamlining algorithms of LIBSA and automating its
disparate protocols will facilitate efficient identification of allosteric binding pockets.
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CHAPTER 3
LBPI: A WEB INTERFACE

3.1

Overview
Ligand Binding Pocket Identification (LBPI) is a Web interface designed for the

identification of allosteric ligand binding sites by employing the protocols of LIBSA. The
protocols include processing of coordinate files followed by molecular docking using
AutoDock, and applying LIBSA filters for removing docking noise and quantifying binding
site preference. LBPI is built on a freely-available Python-based web framework, Django (53),
accompanied by a set of scripts written in the Python programming language that serves as a
Wrapper. The main function of the web framework is to handle requests for uploading or
downloading files, accept modules and parameters that have been passed through the web page,
and return a response to URL to view the contents of the web page. It also stores information
about file location. The Wrapper, on the other hand, helps to process coordinate files, automate
the application of existing algorithms, pass variables to the relevant algorithms, execute
programs and prepare histograms. The platforms to upload or download files, select program
modules, and input user defined parameters and monitor results, are facilitated through the
Web interface accessed via a web browser. The goals of the LBPI Web interface are to make
LIBSA easily accessible to both experts and non-experts and to reduce the significant learning
curve of the technical details needed to perform research independently by non-experts.
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3.2

Python programming and its modules used as a Wrapper
Python (54, 55) is a freely available high-level object oriented programming language

rich in a wide variety of libraries, including scientific libraries extending from bioinformatics
to structural biology. Python programming is chosen for preparing a Wrapper as it requires
fewer line scripts compared to other object-oriented languages such as C++, or C. Hence, it
can be written with fewer errors and is easily understood (56, 57). Python is available in two
versions: Python 2.X and Python 3.X. Since Python 3.X has more updated libraries and
features, it is used in the development of our Wrapper.
Python modules such as sys, re, subprocess, NumPy (58), Matplotlib (59), etc. are used
in the Wrapper for executing existing algorithms, and preparing results. The sys module is
used as a command line argument for accessing the variables used, while the re module,
commonly known as regular expression syntax, is used to match strings and implement
simultaneous jobs designed for each matched string(s). Similarly, the subprocess module helps
to access system commands and is used in executing new processes, followed by piping inputs
and outputs. On the other hand, NumPy and Matplotlib are standard libraries of Python used
for scientific computation and preparing 2D plots. Arrays of data are created by NumPy for
data normalization and plotting of histograms, simple plots or bar plots utilizing Matplotlib.

3.3

Django and its work structure used for web design
Django (53, 60), a freely available Python-based web framework, facilitates

developing, testing and maintaining web applications. Django is very well documented and its
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active community of users continuously update the Django project. Therefore, Django was
chosen as a web framework for LBPI. Some of the scientific projects built on Django web
framework are CHARMMing (61), TargetNet (62), ChemDes (63), and DEPTH (64). The
working of Django starts with creating a project consisting of several sets of codes defined as
applications. Applications of Django include Views, Models, Forms, URLs, and templates.
The workflow of Django is as shown in Figure 3.1.

.
Figure 3.1. The workflow of the Django framework.
A Django template consists of HTML contents, tags (if, else, extend, for etc.) and
variables (which change with the results) for viewing web applications. A Django-powered
site is viewed on a web browser through Django templates containing a specific URL (Uniform
Resource Locator), a web address written in a certain pattern mapped with its Django Views.
Each view in Django application is written as Python function assigning specific tasks, and
hence renders requests and returns responses as Django templates. Django Models cover
essential fields and behaviors of the data to be stored, and derive essential information from
the data. The file field attribute of the model helps in setting folder and file names for the data
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file to be stored. Django Forms are used to accept user inputs as files or data, validate the inputs
and convert them to Python objects.
The Django framework, the Python Wrapper and Web interface templates written in
HTML, complement each other to automate LIBSA protocols, execute jobs and return the
results to the user for the identification of druggable binding sites and quantification of binding
site preferences.
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CHAPTER 4
IMPLEMENTATION OF LBPI

4.1

Overview
As discussed in previous chapters, the goals of LBPI are to make LIBSA easily

accessible to both experts and non-experts and thereby reduce the significant learning curve
needed to use the tool independently. In this chapter we present the implementation of LBPI
in two ways, option 1 and option 2, as shown in Figure 4.1:

Figure 4.1. Front-page of LBPI with two options of use highlighted in box 1. Manual is made
available in the page through the link highlighted in box 2.
Option 1: Process files  perform blind docking  apply LIBSA filters  calculate SNR
This option starts with processing coordinate files for docking, followed by blind
docking and executing LIBSA as illustrated in Figure 4.2.
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Option 2: Process docking files  apply LIBSA filters  calculate SNR
This option starts with processing of a target structure file used for docking and the
docking log files. These files are converted to LIBSA readable formats if needed and serve as
input to LIBSA. The flowchart shown in Figure 4.2 holds true for this application as well,
except that the module for blind docking is skipped and processing of coordinate files is
replaced by processing of docking output files.

Figure 4.2. A schematic outline of the workflow of LBPI.
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4.2

Implementation of blind docking and filters (option 1):

4.2.1 Processing coordinate files
LBPI offers an option for submitting and processing structure files along with example
files for demonstration purposes. Figure 4.3 shows a snapshot of the Web interface for
processing structure files.

Figure 4.3. Choices for submitting coordinate files that are for both the target receptor and
the probe ligand as in the red boxes 1 and 3. Red box 2 represents a list of PDB chain
identifiers and co-crystals that exist in the target structure returned to the user for selection.
For docking, the blue box highlights example files provided for demonstration purposes.
The process of submission and preparation of the target structure for molecular docking
is done automatically. Submission of a structure or structures can be done in two ways: a)
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uploading a file in a pdb or mol2 format or b) providing a valid 4 letter PDB id for retrieving
the structure from the protein data bank. The Python snippet shown in Figure 4.4 highlights a
function in Django Views that handles the user request for submitting the structure via the
POST method. Document and Document Form used in the script are defined as functions in
Django Models and Django Forms for storing the file in a defined folder, and handling file
submission, respectively. A structure submitted by providing valid pdb id is handled through
the GET method.

Figure 4.4. Python snippet from Django Views representing a function which accepts and
returns user requests for submitting files via the Web interface.
The Wrapper invoked through Django Views after submission of the target file assists
in the conversion of a mol2 file format to a pdb file format by means of Open Babel (65).
Figure 4.5 shows a snippet from the Wrapper used for extracting chain identifiers and cocrystals that might be present in the coordinate file. A list is then returned to the user for
selection of chains and co-crystals to be included in the target structure for docking. The
prepared structure is then processed automatically with tasks such as renumbering of residue
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id, addition of atomic Gasteiger charges and polar hydrogens, removal of ions and water
molecules by invoking Python scripts in MGL Tools of AutoDock, via the Wrapper.

Figure 4.5. A Python snippet from the “Wrapper” for extracting chain identifiers and
residue names to facilitate returning of a list of chain identifiers and co-crystals to the user.
Similarly, the probe ligand can be submitted in pdb, sdf, smi or mol2 file formats. It
can also be submitted as line notation entry termed as SMILES (simplified molecular-input
line-entry system) (66). The Wrapper converts SMILES strings to a 3D coordinate file in pdb
format utilizing Open Babel. The ligand coordinate file is then made available for download
through the Web interface to confirm if the desired structure has been generated. The working
of Django framework for handling submitted structure for ligand and processing of prepared
ligand structure is similar to that explained for processing of the target structure.
4.2.2 Docking of the probe on the entire surface of the target protein
Following the preparation of coordinates of the probe and the target molecule, the
Wrapper calculates the size of the target molecule to map a cubical grid on the entire surface
of the target to define the search space for docking. The parameters required for blind docking
can be provided through the Web interface as shown in Figure 4.6, which include:
Spacing is the distance in Å between the centers of two grid points, with the same value used
in every dimension for a cubic box. The default (recommended) value depends on the size of
the target and ranges from 0.1 Å to 1 Å.
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Energy evaluations is the maximum number of energy evaluations to be performed during
docking. Its value ranges from 250,000 to 25,000,000 depending on the number of rotatable
bonds present in the probe ligand, with the default being 250,000.
Number of generations is the maximum number of generations a docking should attain to
terminate the run. The default is 27,000, which is sufficient for ligands with less than 10
torsions.
Number of runs refers to the number of independent runs to be requested for docking. Its
maximum value is 256 and is used as default.

Figure 4.6. Parameters required for blind docking shown in the red box. Blue box highlights
downloadable ligand coordinate files generated by LBPI.
The parameters submitted through the Web interface are handled by Django Views by
the code snippet shown in Figure 4.7, which is then passed to the Wrapper through system
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arguments as shown in Figure 4.8, for executing specific tasks assigned as shown in Figure
4.9.

Figure 4.7. Python snippet from Django Views showing the method used to accept input
parameters.

Figure 4.8. Python snippet from the “Wrapper” representing system arguments for passing
parameter values retrieved from the framework shown in Figure 4.7.

Figure 4.9. Python snippet from the “Wrapper” showing the passing of parameter values
through system arguments to invoke Python scripts present in MGL Tools of AutoDock for
preparing parameter files needed for docking.
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Figure 4.10. Grid box mapping the surface of the protein with its center overlapping the
center of the protein.
The maximum length of the target protein structure in each direction represents the
length of the cubic grid box after adding 10 Å in each direction to accommodate the ligand in
the search space. For a cubic box of length l, the recommended spacing (Srec) for efficient
calculation of interaction energies is Srec =

𝑙
126

Å, where 126 is the maximum total number of

grid points allowed in AutoDock. For Srec ≥ 1 Å, Srec is set to 1 Å as AutoDock has a spacing
(S) limit of (0.10 ≤ 𝑆 ≤ 1) Å. If a user provides a spacing value through the Web interface,
the number of grid points (N) is calculated as,
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With the adjustment of the grid box around the protein surface with its center located
at the center of the protein, and using the parameters provided through the Web interface, the
Wrapper invokes corresponding AutoDock Tools for blind docking. The target file used for
docking and the docking log file obtained from docking are then converted to LIBSA readable
formats to execute LIBSA.
4.2.3 LIBSA filters
The module for LIBSA filters in the Web interface is as shown in Figure 4.11.
Histograms for contact and affinity spectra from docking are displayed through the Web
interface to help the user decide about the filter to be used for removing docking noise.
Histograms are prepared with the help of the Wrapper using NumPy and Matplotlib library as
shown in Figure 4.12, which is then returned to the user through the Web interface.
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Figure 4.11. LBPI facilitates selection of LIBSA filters with parameters for corresponding
selected filters as shown in red boxes. Blue box 1 represents processed log files available for
download, which can be viewed with any graphical interface. Histograms provided in blue
box 1 represent affinity and contact spectra obtained from docking without utilizing filters.
Histograms in blue box 2 represent affinity and contact spectra after applying LIBSA filters.
SNR values are provided along with the residues representing the region of interest.
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Figure 4.12. Python snippet of scripts written for preparing NumPy array used by Matplotlib
as pl for preparing histogram.
If LIBSA filter is selected, the Web interface allows the user to input the appropriate
parameters. These parameters include bin size, which is the width of bins to be used when
calculating histograms; threshold, which refers to the cut-off for the peak height ranging from
0 to 1 due to normalization, peak values less than the defined threshold are excluded; sampling
bin size 1 to 100, the number of bins to the left and right of the selected explicit peak; and cutoff, the distance between any heavy atom of the ligand and the target in Å for calculating the
number of contacts. The default value for each parameter is provided based on the
recommendations in the original Journal article (49). When the parameter values are submitted
through LBPI, the Wrapper automates the execution of LIBSA and returns the results to the
user through LBPI. Figure 4.13 represents a snippet of a function based on the selection of data
through LBPI. A function in Django Views assigned for the corresponding filter passes the
parameter values and executes the LIBSA algorithm for affinity filtering. Finally, the results
are returned to the user as an HTML page in LBPI.
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Figure 4.13. Python snippet from Django framework for selecting filters.

Based on the selection of LIBSA filters through LBPI, a contact histogram is calculated
and returned to the user for them to decide on parameters to be provided for calculating SNR.
These parameters include peak value, which refers to the minimum value of the dominant
peaks in the contact spectrum to be considered for locating residues representing the center of
region of interest. Then neighboring residues within a certain distance of these central residues
that satisfy the peak histogram criterion are selected to define a binding region of interest. This
region serves as a signal to calculate SNR through LBPI.
4.2.4 Ensemble-based SNR
LBPI facilitates uploading of multiple receptor conformations through the ‘For
ensembles’ button provided in the processing of receptor section. All conformations should
consist of an equal number of atoms and should be in the pdb file format. When uploaded,
these conformations are saved in separate folders and are processed separately with the help of
the Wrapper. At least 2 target conformations should be uploaded. A probe ligand is then
uploaded, processed and sent to each folder for docking, application of filters and obtaining
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contact and affinity spectra independently. Next, by means of the Wrapper, a single contact
spectrum and affinity spectrum is produced by averaging the corresponding spectra obtained
for each target conformation. Finally, a binding region of interest is identified and SNR is
calculated for the identified region of interest to get a best binding site for the ensemble.

Figure 4.14. Uploading multiple conformations to calculate SNR by averaging over an
ensemble.
4.3

Implementation of filters (option 2)

4.3.1 File preparation
In this section, a target pdb or mol2 file used in molecular docking or obtained in a
pdbqt format from AutoDock is accepted and processed as a LIBSA readable format. For the
probe, a dlg file from AutoDock is accepted and similarly processed. The processed dlg file
includes conformation of the probe from docking with its corresponding binding energy.
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Figure 4.15 shows a snapshot of this section from the Web interface. This section then proceeds
to the utilization of filters as the module for blind docking is skipped in this section.

Figure 4.15. Options for submitting files of the receptor and log files from docking is
highlighted in the red box with example files highlighted in the blue box.
4.3.2 LIBSA filters
LIBSA filters in this section is similar to the one described in section 4.2.3 and shown
in Figure 4.11. The filters selected, parameters provided and histograms prepared through the
Web interface in this section are as explained in section 4.2.3 for the identification of
appropriate binding site and quantification of its binding site preference.

4.4

Summary
We have shown that LBPI has been implemented in 2 ways to enable flexibility. Option

1 is mainly targeted to non-experts who would like to focus on the identification of binding
sites using LIBSA protocols without the knowing technical details of molecular docking or
LIBSA filters. However, the advantage of choosing option 2 over option 1 is that users
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(especially experts) can directly focus on the application of LIBSA filters by skipping
molecular docking. Also, users can choose a wide range of customizable parameters for
molecular docking to obtain log files required for LIBSA filters instead of conducting docking
with AutoDock via LBPI. However, this section is feasible to experts who are acquainted with
molecular docking. Our implementation of LBPI thus allows users the flexibility necessary to
select the modules on the basis of their preference.
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CHAPTER 5
APPLICATIONS

5.1

Re-docking with LBPI
We applied LBPI on three protein-ligand complexes (mentioned as cases in Table 1

and throughout this section) taken from the protein data bank for re-identifying the known
binding site of their co-crystal ligand. For each case, first, we used LBPI for extracting the
protein structure from the PDB and then uploaded the corresponding ligand coordinate
extracted from the complex structure utilizing Visual Molecular Dynamics (VMD), a graphical
interface (67). The information about proteins and ligands used are shown in Table 1 and
Figure 5.1. Next, we provided parameters to LBPI for molecular docking (mentioned in Table
1) and LIBSA filters (default parameters were used). The submission of these parameters to
LBPI executed molecular docking and LIBSA filters automatically. The results obtained and
the site identified via LBPI are shown in Table 1 and Figure 5.2. For cases 1 and 2, we
identified a single binding region of interest (green region) for the corresponding ligands and
compared with it with the known binding site (the region with the ligand shown in red). The
identified region agrees well with the known binding site. Also, the value of the computed
SNR for these regions was greater than 1 (Table 1, Figure 5.2), illustrating that LBPI
successfully identified the known binding sites as preferred binding sites for cases 1 and 2. For
case 3, we identified two potential binding sites (green and blue regions in panel C, Figure 5.2)
and compared their SNR values. As the SNR for the green region is higher than the blue region,
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we conclude that the green colored binding region (Figure 5.2, panel C) is the preferred binding
site, which remarkably coincided with the known binding site.

Figure 5.1. Chemical structures of ligand 0QV, SB2, and EST from PDB 4EPW, 1QKT and
1A9U respectively.
To put it briefly, by directly submitting coordinate files of the proteins and known cocrystallized ligands and other parameters to LBPI, we were able to identify the correct binding
site for all three cases without reverting to manual procedures or knowing the technical details
of the molecular docking protocol or LIBSA filters.
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Figure 5.2. (A-C) Contact histograms after applying affinity and highpass filter to remove
docking noise (left). The target structure shown in grey surface with the co-crystallized
ligand is represented in red and the docked poses in black dots; SNR for the region of
interest is shown in the right panel and is highlighted in green on the protein surface, which
coincides with the co-crystal site.
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Table 1. Summary of re-docking results with LBPI
Case

PDB
id

Co-crystallized ligand

Protein

1

4EPW

0QV
(4-hydroxypiperidin1-yl)(1H-indol-3yl)methanethione
EST
(estradiol)

K-Ras

2

3

1QKT

1A9U

SB2
4-[5-(4-fluorophenyl)-2-(4methanesulfinylphenyl)-3h-imidazol4-yl]-pyridine

Docking
parameters
(E.E., N.G.)*
2.5*106

SNR (predicted
binding site residues)
1.672 (7, 39, 55, 56,
57, 70, 71, 72, 74)

2.7*104
Nuclearestrogen
receptor

2.5*105

Kinase
protein
(P38)

2.5*105

2.7*104

2.7*104

1.582 (42, 43, 44, 80,
81, 82, 83, 84, 86, 85,
88, 100, 101, 102,
219, 221, 223)
1.198 (47, 79, 80,
103, 104, 105, 106,
107, 155, 156, 157,
161, 162, 163)
0.921 (233, 235, 236,
237, 263, 264, 265,
286, 287, 288)

* E.E. = energy evaluations and N.G. = number of generations

5.2

Cross-docking with LBPI
We demonstrated an additional use of LBPI by performing cross-blind docking of

ligand NIL (obtained from 3GP0) to a kinase-protein, P38, obtained after removing the cocrystals in 1A9U. The coordinate files were submitted to LBPI as mentioned earlier, and
parameter values were provided to LBPI in a similar way as case 2, shown in Table 1. The
result obtained after executing molecular docking and application of LIBSA filters through
LBPI is shown in Figure 5.3. The calculation identified two regions as binding regions of
interest, shown in green and blue regions on the protein structure in Figure 5.3, along with the

36

SNR. Since SNR for the green region is higher, it is considered a preferred binding site as
compared to the blue region.

Figure 5.3. Contact histogram after affinity and high pass filtering of docking results for NIL
(3GP0) to protein kinase P38 (1A9U).
The crystal binding site of ligand NIL in 3GP0 is similar to the crystal binding site of
ligand SB2 in 1A9U (68, 69). On comparing the preferred binding region obtained from LBPI
with the known crystal binding site, we could say that LBPI was able to locate the correct
binding site from cross docking of NIL on P38.
Further, for a rigorous test, we took four different ligands 0QR (N-(6-aminopyridin-2yl)-4-fluorobenzenesulfonamide), 0QW ((2-hydroxyphenyl)(pyrrolidin-1-yl) methanethione),
0QX (2-(1H-indol-3-ylmethyl)-1H-imidazo[4,5-c] pyridine) and BZI (benzimidazole) from
PDB- 4EPX, 4EPT, 4EPV and 4DSU respectively (Figure 5.4), and cross-docked them to
GDP-bound K-Ras using 4EPW crystal structure, after removing all co-crystals. As discussed
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in earlier sections, the coordinate files and parameters were provided to LBPI. The parameters
values used were similar to case 1 shown in Table 1.

Figure 5.4. Chemical structures of ligands 0QR, 0QW, OQX and BZI from PDB 4EPX,
4EPT, 4EPV and 4DSU respectively
Docked poses obtained from docking through LBPI were rendered with VMD for each
ligand and shown in Figure 5.5. The histograms prepared by LBPI after executing LIBSA
filters are shown in Figure 5.6. The ligands we have chosen for cross docking are known to
bind at the same site as the co-crystallized ligand 0QV in 4EPW (70, 71). When cross-docked,
LBPI identified two regions of interest, region 1 (pink) and region 2 (cyan) for each ligand,
except for BZI, which has only one predicted site, region 1 (pink). After computing the SNR
values (Figure 5.6) for the identified regions through LBPI and comparing them, the ligands
could be ranked as BZI > 0QX > 0QW > 0QR for their binding preference to region 1, and
0QW > 0QX > 0QR > BZI for their binding preference to region 2. LBPI correctly identified
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region 1 as the preferred binding site for 0QX and BZI but failed for ligands 0QR and 0QW,
as the SNR for region 2 was higher than the SNR for region 1 for these ligands.

Figure 5.5. Docked poses obtained from AutoDock for 0QR (blue), 0QW (yellow), 0QX (red)
and BZI (green). Regions 1 and 2 are represented by pink and cyan color respectively and
indicate the binding regions of interest for calculating SNR for each ligand.
Since the ligands used for cross docking were selected from PDB files of the same
protein but of different conformations, each protein conformation might differ in terms of the
size and volume of the correct binding site. Thus we checked if re-docking of 0QW and 0QR
to their parent protein structure through LBPI could identify the appropriate binding site. The
procedure for submitting coordinate structures and parameter values to LBPI was the same as
mentioned before. Our results (Figure 5.7) show that only one binding site was identified for
0QW, whereas, once again, two possible sites were identified for 0QR. The computed SNR for
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the predicted regions of interest for both 0QR and 0QW suggest that the preferred binding site
identified by LBPI coincides with the known binding site for both ligands.

Figure 5.6. Panels A, B, C, and D represent contact histograms for 0QR, 0QW, 0QX and BZI
after docking on K-Ras (4EPW) and applying both affinity and high pass filters. SNR
computed for region 1 is represented in pink and SNR computed for region 2 is represented
in cyan.
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Figure 5.7. Contact histograms for 0QR and 0QW obtained from docking these ligands to the
parent protein X-Ray structure. SNR for region 1 and region 2 is represented as pink and
blue respectively.
However, the SNR computed for 0QR when docked on a single K-Ras structure of
PDB id 4EPW or 4EPX is still less than 1. I believe this is because the docking protocol did
not account for the flexibility of the target protein. With the incorporation of receptor
flexibility, the conformational space sampled gets improved (72, 73) and thereby the
probability of finding the right binding site with better SNR values. To check this, we selected
5 different conformations of K-Ras from an MD simulation for ensemble blind docking of
0QR and 0QW. We submitted the five conformations of K-Ras and that of the ligand to LBPI.
Using the default parameters, we executed docking and LIBSA filters for each conformation
and averaged the results to obtain a single spectrum. Figure 5.8 and Figure 5.9 show contact
histograms for each conformation as well as the single average contact histogram obtained
after averaging the contact histograms of each conformation. Visual analysis of the results
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shows two probable binding regions in some of the conformations for 0QR but just one for
0Qw. However, the result of the average spectrum suggests a single binding region with SNR
> 1 for both 0QW and 0QR. The region agrees well with the known binding site in the X-Ray
structure. Hence, we conclude that LBPI can successfully identify the preferred binding site of
a protein with single conformation or multiple conformations and a diverse set of ligands
without manually performing molecular docking and LIBSA analysis.

Figure 5.8. Contact histograms after blind docking of 0QR on five K-Ras conformers (A to E)
and a single averaged contact histogram (F).
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Figure 5.9. Contact histograms after blind docking of 0QW on five K-Ras conformers (A to
E) and a single averaged contact histogram (F).
5.3

Identification of binding sites of test ligands with LBPI
We used LBPI on three test ligands promazine, E22, and V2, for the identification of

their potential preferred binding site on the K-Ras protein structure PDB id 4EPW. The
experimental analysis in our lab suggested that all three ligands may bind to the same site that
coincides with a known binding site for ligand 0QV in PDB 4EPW. We utilized LBPI to extract
K-Ras structure from 4EPW and submitted our test ligands through the Web interface. Default
parameters were provided to LBPI to conduct docking and LIBSA analysis. The results (Figure
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5.10) show that the predicted binding site of promazine agrees well with our experimental
analysis whereas the predicted binding site for E22 and V2 differs from the expected site. This
could be due to the limitation of using a single X-Ray structure, as discussed in the previous
section. To check if using multiple conformations would help, we utilized five conformations
of K-Ras obtained from an MD simulation. The coordinate files were uploaded and default
parameters were submitted via LBPI for executing molecular docking and application of
LIBSA filters.

Figure 5.10. Contact histograms for three test ligands promazine (A), E22 (B) and V2 (C)
docked on X-Ray structure 4EPW of K-Ras.
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Visual analysis of the results for each conformation (Figure 5.11 and Figure 5.12)
indicated two distinct binding sites for both E22 and V2, depending on the conformation of KRas used for docking. However, when averaged, a single region was identified as a preferred
binding site for E22 and V2 with a computed SNR of 1.165 and 1.339, respectively. The SNR
>1 indicates that this is the potential binding site for both ligands, which agrees well with our
experimental results. In summary, LBPI was able to identify potential binding sites for our test
ligands, particularly if multiple target conformations are used.

Figure 5.11. Contact histograms after blind docking of E22 on five K-Ras conformers (A to
E) and a single averaged contact histogram (F).
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Figure 5.12. Contact histograms after blind docking of V2 on five K-Ras conformers (A to E)
and a single averaged contact histogram (F).
5.4

Identification of the binding preferences of estrogens with LBPI
Estrogens are hormones responsible for the development and balance of the female

reproductive system (74). Estradiol, estrone, and estriol are the most common naturally
occurring estrogens (75). Some of the other estrogen compounds including 17 alpha estradiol,
ethinyl estradiol and, estradiol valerate are either naturally occurring or artificially synthesized.
All of these estrogenic compounds are clinically used as steroidal estrogens (75). These
compounds bind to estrogen receptor proteins and induce conformational changes in the
protein. From the data available in the literature, the relative binding affinity of these
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compounds (Table 2) for estrogen receptor alpha is ethinyl estradiol > estradiol > estrone > 17alpha estradiol > estriol > estradiol valerate (74-77) To study the predicted binding preference
of these estrogen compounds using LBPI, we docked these compounds on the structure of
estrogen receptor protein extracted from pdb id 1QKT, after removing its co-crystal through
LBPI followed by the use of LIBSA filters to identify a potential binding site for each
compound. 2.5*106 energy evaluations and 27000 number of generations were used for
docking and default parameters were used for LIBSA filters. The results are shown in Figure
5.14 and Table 2. Estradiol and 17-alpha estradiol are stereoisomers and differ in their binding
affinity by two folds, with estradiol binding more strongly to estrogen receptor (78). However,
the results obtained from LBPI show minor differences in binding affinity of these compounds
(Table 2). Similarly, for other estrogenic compounds, identical binding pattern was seen with
minor differences due to the change in very small group present in the 17th position of estradiol,
except for estradiol valerate. Estradiol valerate, which possesses valerate group was larger than
any groups present at the 17th position of estradiol and has a higher number of rotatable bonds
and thus the difference observed in its binding affinity was notable.
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Table 2. Relative binding affinity for estrogen compounds from literature and summary of
results obtained from LBPI.

Compounds

Relative
binding
affinity

Affinity
from
LBPI

Estradiol

1

-9.6

42, 43, 44, 83, 84, 85, 86, 88, 100, 101,
102

1.581

Estradiol
17-alpha

0.58

-9.2

42, 43, 44, 80, 81, 83, 84, 85, 86, 88,
100, 101, 102

1.420

Estradiol
valerate

0.02

-6.8

2, 3, 4, 59, 60, 61, 62, 63

1.115

219, 221, 222, 223, 224

1.136

Residues identified by LBPI

SNR
from
LBPI

Estriol

0.14

-9.3

42, 43, 44, 80, 81, 82, 83, 84, 85, 86, 88,
100, 101, 102, 219, 220, 221, 222, 223

1.733

Ethinyl
estradiol

2.33

-9.9

42, 43, 44, 80, 81, 83, 84, 85, 86, 88,
100, 101, 102, 220, 221, 222

1.332

Estrone

0.6

-10.15

42, 43, 44, 80, 81, 83, 84, 85, 86, 88,
100, 101, 102

1.455

The results (Table 2, Figure 5.14) obtained from this study suggests that through LBPI
energy values obtained were not significantly different for estrogen compounds. This is
because the compounds are structurally very similar. On the other hand, estradiol valerate has
larger valerate group attached at the 17th position of estradiol and thus the difference observed
was significant. This demonstrates the limitation of the docking program and suggests that to
study substantial changes in binding affinity of a compound and its derivatives, there should
be a significant difference in their structures. However, LBPI was able to identify the correct
binding site for estrogen compounds except for estradiol valerate (Table 2). For estradiol
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valerate, two binding sites were observed out of which the most preferred binding site based
on calculated SNR through LBPI was able to capture some of the surrounding residues of the
correct binding site.

Figure 5.13. Chemical structure of estrogen compounds
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Figure 5.14. Contact histograms obtained after applying affinity and high-pass filters to
remove docking noise for estrogen compounds to estrogen receptor (1QKT).
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5.5

Identification of allosteric ligand binding site for sorafenib on p38 through LBPI
Compounds targeting the ATP binding site for modulating the function of kinase

proteins are identified as inhibitors e.g. binding of SB2 to P38 as shown in Figure 5.2 case 3
(69). Research has also been performed in investigating compounds that alter the function of
proteins through allosteric modulation without directly binding to the ATP binding region.
Sorafenib has been identified as a notable allosteric inhibitor that binds to the region
immediately next to the ATP binding region of kinase protein and modulates the function (79,
80). To identify a potential binding site for sorafenib in kinase protein (P38) through LBPI, we
extracted the structure of P38 from pdb id 3HEG and performed docking with its co-crystal
sorafenib (BAX) utilizing LBPI. 2.5*106 energy evaluations and 27000 number of generations
were used for docking and default parameters were used for LIBSA filters. Three binding sites
were identified through LBPI represented as blue, green and pink (Figure 5.15), of which the
blue region coincides with the known binding site and it is the favorable binding site as it has
SNR greater than 1. Hence, LBPI was able to identify the correct binding site as the preferred
binding site for sorafenib.
When we compare the results obtained from LBPI for identifying potential binding
sites for SB2 on P38 (Figure 5.2, case 3) and sorafenib on P38 (Figure 5.15), LBPI was able
to correctly identify the catalytic binding site for SB2 and allosteric binding site for sorafenib
respectively. We can thus conclude that, in the long run LBPI can be used for identifying
potential binding sites be it catalytic or allosteric for any drug targets.
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Figure 5.15. Contact histogram after affinity and high pass filtering of docking results for
sorafenib to its protein kinase P38 (3HEG) shown in left panel, structure of P38 with docked
poses in yellow, three identified region from LBPI, co-crystal (sorafenib) in red, and chemical
structure of sorafenib in right panel.

52

CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

Computational approaches introduced for identifying allosteric ligand binding sites e.g.
LIBSA requires expert skills to be properly executed and hence limits its users. Building a
computational pipeline as a web interface by automating protocols will bridge the gap and help
users focus on the biological applications. We have presented a Web interface, LBPI, which is
built on Django, a Python framework, supplemented by a Python Wrapper, for automating the
protocols of LIBSA, executing it and monitoring the results. LBPI is implemented in two ways
to allow users flexibility. Option 1 is mainly targeted to inexperienced users for applying
LIBSA protocols without undergoing technical details for docking and LIBSA filters. On the
other hand, option 2 is mainly targeted to users who are expert in molecular docking and can
directly focus on utilizing LIBSA filters by skipping molecular docking through the Web
interface. The user manual and example files provided through the Web interface will help
users to get better acquainted with the workings of LBPI. Through LBPI, by submitting
structure files for target and probe ligand of appropriate file format, providing few
customizable parameters and selecting modules for LIBSA filters will help in the effective
identification of binding sites without understanding technical details.
For demonstration purposes of LBPI, we have used three known protein-ligand
complexes, and directly submitted coordinate files of those proteins and their co-crystallized
ligands and other parameter values to LBPI to successfully identify their correct binding sites
without manual procedures. Further, from cross docking of a diverse set of ligands on different
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target conformations obtained from the protein databank, we showed that there are cases where
LBPI fails to identify the correct binding site. This was largely due to the limitation of using a
single X-Ray structure for the target, which might be unsuitable in terms of the size and volume
of the binding pocket. This suggests that for effective identification of a binding site, a single
structure may not be sufficient. Hence, we have demonstrated that LBPI was able to correctly
identify predicted binding sites for each ligand when multiple target conformations from MD
simulation are used. We have also shown that LBPI helps rank ligands based on SNR
calculated for a preferred site. We have also shown the use of LBPI for a successful
identification of preferred binding sites (based on experimental analysis done in our lab) for
test ligands on a single X-Ray structure or multiple target conformations. Further, we utilized
LBPI to study the predicted binding preference of different estrogenic compounds. It is due to
the limitation of docking program which failed to show the substantial change in the binding
affinity as the estrogenic compounds used in LBPI had very minor change in the structures.
However, it was able to locate the correct binding site for each estrogen compounds, which is
the major goal of LBPI. Finally, LBPI was able to correctly identify catalytic and allosteric
site for catalytic and allosteric inhibitor respectively, through which we can conclude that LBPI
is capable of identifying potential binding site of a ligand based on preference of binding to a
site.
We have demonstrated the successful use of LIBSA through LBPI for diverse set of
drugs but only a few target structures. However, Hocker et al. in the original paper of LIBSA
have demonstrated its application for a more diverse set of druggable targets (49). Thus we
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expect that LBPI will be utilized on even more challenging drug targets for the identification
of potential binding site(s). The time required for executing LIBSA filters and performing
docking through LBPI is comparable to standalone LIBSA. However, the efforts required to
prepare structure files, understand technical details for performing docking and executing
LIBSA algorithms is reduced significantly through LBPI. The demonstration for the
performance of LBPI on a set of examples was done locally in our lab. Our next goal is to work
on making it available through the Internet to make it easily accessible to both experts and nonexperts and reduce the significant learning curve for understanding the technical details and
focus more on biological applications. We can facilitate the calculation of SNR based on
residues provided by the users. Next, we can add the ensemble approach in option 2 for
focusing the use of LIBSA filters for ensemble. Furthermore, we have a clear vision of adding
pMD protocols (developed in our lab) to LBPI, which consist of MD simulation in presence
of probe(s) to assess the propensity of a site in a wide variety soluble or membrane proteins
(48).
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